date:Nov 13, 2018
feel there's no reason to stop, Manson said.
Others may want to wait because we are going to be publishing findings for other endpoints - diabetes, cognitive function, depression, autoimmune diseases - over the next six months, she said. These findings may help people decide if the benefits are likely to outweigh the risks for them.
And people should not be taking higher doses than what was used in the study, Manson noted. With megadoses, the risk may outweigh the benefit. With high doses of